Market revenue in 2023 | USD 1,439.1 million |
Market revenue in 2030 | USD 2,852.0 million |
Growth rate | 10.3% (CAGR from 2023 to 2030) |
Largest segment | Anti-infective |
Fastest growing segment | Chemotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals |
Key market players worldwide | CVS Group PLC, Walgreens Boots Alliance Inc, UnitedHealth Group Inc, BrightSpring Health Services Inc, Fresenius Medical Care AG, ICU Medical Inc, B. Braun Medical, Baxter International Inc, BD, Smiths Group PLC, Terumo Corp, Caesarea Medical Electronics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to home infusion therapy market will help companies and investors design strategic landscapes.
Anti-infective was the largest segment with a revenue share of 26.92% in 2023. Horizon Databook has segmented the China home infusion therapy market based on anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, specialty pharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing number of key players entering the home healthcare market due to low expenses and availability of skilled workforce, such as nurses, are likely to drive the growth of the home infusion therapy market in China during the forecast period. In its 12th Five Year Plan (2011–2015), China allowed private institutions to set up healthcare establishments and nursing facilities.
In line with this, several joint ventures between the U.S. health providers or investors and Chinese senior care companies are currently underway in the country. Moreover, increasing number of product launches pertaining to home infusion is expected to contribute to market growth. In addition, rising geriatric population is likely to boost the demand for home healthcare in China during the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the China home infusion therapy market , including forecasts for subscribers. This country databook contains high-level insights into China home infusion therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account